Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued ADT after PVI in Persistent AF (POWDER-AF2)
NCT03437356Completed
- Sponsor
- AZ Sint-Jan Brugge
- Start
- Feb 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Randomised, single-blind trial of flecainide, propafenone and sotalol in Atrial fibrillation (AFib) (2 arms), sponsored by AZ Sint-Jan Brugge. Primary endpoint: Atrial Tachyarrhythmia Recurrence. Started Feb 2018; status: completed.
02
Drugs
flecainidepropafenonesotalol
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03437356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437356.